IVORY Study Video
- 16/07/2026
Video description
Human Milk Oligosaccharides (HMOs) are third largest solid component of breastmilk that help support the development of an infant's immune system. After decades of research, Nestlé Health Science has become the first to incorporate two structurally identical HMOs, 2'FL and LNnT, into a hypoallergenic formula.
This video highlights findings from the IVORY Study, the first study of its kind to assess HMOs in infants and young children with Cow's Milk Protein Allergy (CMPA). Discover how the formula demonstrated safety, tolerance, and compliance with gold-standard clinical hypo allergenicity requirements, offering clinicians a new option for nutritional management of CMPA.